PCM
SUPN icon

Prelude Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Prelude Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,046
Closed -$22K – 1954
2020
Q3 		$22K Sell
1,046
-2,596
-71% -$58.9K ﹤0.01% 1316
2020
Q2 		$86K Buy
+3,642
New +$80.5K ﹤0.01% 1001
2019
Q1 		– Sell
-2,948
Closed -$110K – 2156
2018
Q4 		$98K Buy
+2,948
New +$127K 0.01% 941
2018
Q3 		– Sell
-9,860
Closed -$487K – 2022
2018
Q2 		$590K Buy
9,860
+286
+3% +$14.8K 0.04% 483
2018
Q1 		$438K Buy
9,574
+800
+9% +$33.4K 0.03% 480
2017
Q4 		$350K Buy
8,774
+2,296
+35% +$90.7K 0.03% 504
2017
Q3 		$259K Hold
6,478
– – 0.02% 564
2017
Q2 		$279K Sell
6,478
-3,067
-32% -$109K 0.03% 474
2017
Q1 		$299K Buy
9,545
+2,488
+35% +$66.7K 0.03% 434
2016
Q4 		$178K Sell
7,057
-7,941
-53% -$177K 0.02% 623
2016
Q3 		$371K Buy
14,998
+2,917
+24% +$66K 0.04% 366
2016
Q2 		$246K Sell
12,081
-7,846
-39% -$139K 0.03% 438
2016
Q1 		$304K Buy
19,927
+9,327
+88% +$122K 0.04% 401
2015
Q4 		$142K Buy
10,600
+7,200
+212% +$111K 0.02% 686
2015
Q3 		$48K Sell
3,400
-300
-8% -$5.58K 0.01% 1074
2015
Q2 		$63K Sell
3,700
-2,100
-36% -$29.9K 0.01% 1067
2015
Q1 		$70K Sell
5,800
-14,300
-71% -$135K 0.01% 1161
2014
Q4 		$167K Buy
+20,100
New +$169K 0.02% 743

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Prelude Capital Management's SUPN Position: Q4 2020 in Review

Prelude Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2020, closing a stake of 1,046 shares — an estimated $22K sold.

Prelude Capital Management first reported a position in SUPN in Q4 2014 and held it in 18 quarters. The position peaked at $590K in Q2 2018. 225 funds tracked by Wall St. Rank hold SUPN as of Q4 2020.

  • Prelude Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 1,046 Supernus Pharmaceuticals shares in Q4 2020, an estimated $22K.
  • Prelude Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 18 quarters.
  • Prelude Capital Management's Supernus Pharmaceuticals position peaked at $590K in Q2 2018.
  • 225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.